In July, Cynata received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering the use of its Cymerus™ MSCs in treating asthma and allergic airways disease. The patent adds yet another string to the Company’s bow which now has multiple applications under investigation for its off-the-shelf stem cell product.